For decades, general health and science information has served as the foundation for public understanding of medical risks and therapeutic benefits. In this legacy context, audiences were educated about broad wellness principles, disease prevention, and the importance of evidence-based treatments. This foundational knowledge naturally extends to more specialized areas, such as the long-term use of prescription medications and their potential side effects. One such medication, Fosamax (alendronate), was widely prescribed for osteoporosis, a condition affecting bone density. As public awareness grew, so did scrutiny of rare but serious adverse events associated with its use, including osteonecrosis of the jaw (ONJ). This condition, characterized by bone death in the jaw, became a focal point for patients and healthcare providers alike. The transition from general health literacy to a specific concern about Fosamax exposure and ONJ risk reflects a natural progression in medical discourse. For individuals in Arizona who have taken Fosamax and subsequently developed jaw complications, understanding the legal landscape—particularly the statute of limitations—becomes critical. This shift from broad health education to targeted legal and occupational exposure concerns underscores the need for precise, actionable information.
Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax has been reported to vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is rare, and the incidence of atypical femoral fracture is uncommon (https://pubmed.ncbi.nlm.nih.gov/42046648/). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The safety and tolerability profiles of once-weekly Fosamax 70 mg and daily Fosamax 10 mg were similar in a one-year study (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
From a medical perspective, the clinical presentation of ONJ typically involves exposed necrotic bone in the maxillofacial region, often with pain, swelling, and infection. Diagnosis is based on clinical examination and imaging, and management may include conservative measures, antibiotics, and surgical debridement. The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are thought to involve suppression of bone turnover, impaired angiogenesis, and altered immune response, leading to compromised healing of the jawbone after dental procedures or local trauma. Regarding risk considerations, the adequacy of warnings about Fosamax and ONJ is documented in the prescribing information, which includes a specific section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, patients and healthcare providers should be aware of the potential for ONJ, especially with long-term use and in the presence of risk factors. For affected patients in Arizona, attorney-related considerations include the statute of limitations for filing a claim. The statute of limitations for personal injury claims in Arizona is generally two years from the date of injury or from the date the injury was discovered or should have been discovered with reasonable diligence. For claims involving Fosamax and ONJ, the timeline between exposure and documented harm is critical. ONJ can develop months to years after starting Fosamax, and the time to onset of symptoms can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Patients who have been diagnosed with ONJ after using Fosamax should consult with an attorney to determine the applicable statute of limitations in Arizona, which may depend on the specific facts of the case, including when the injury was discovered. In summary, Fosamax is associated with a rare risk of ONJ, with known risk factors and a variable time to onset. The prescribing information includes warnings about this adverse effect. Patients in Arizona who have developed ONJ after using Fosamax should be aware of the statute of limitations for filing a claim and should seek legal advice promptly.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Arizona, the statute of limitations for personal injury claims is generally two years from the date of injury or from the date the injury was discovered or should have been discovered with reasonable diligence. For Fosamax-related ONJ, the timeline between exposure and diagnosis is critical, and patients should consult an attorney promptly to determine the applicable deadline based on their specific circumstances.
Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk may increase with longer duration of bisphosphonate use.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.